Melanie Healey - Aug 23, 2023 Form 4 Insider Report for Kenvue Inc. (KVUE)

Role
Director
Signature
/s/ Alla Berenshteyn, as attorney-in-fact
Stock symbol
KVUE
Transactions as of
Aug 23, 2023
Transactions value $
$0
Form type
4
Date filed
8/25/2023, 05:51 PM
Previous filing
Jul 5, 2023
Next filing
Sep 13, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KVUE Common Stock Other +151 151 Aug 23, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KVUE Deferred Share Units Award $0 +7.62K $0.00 7.62K Aug 23, 2023 Common Stock 7.62K Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 24, 2023, Johnson & Johnson commenced a registered exchange offer to holders of shares of Johnson & Johnson common stock to exchange Johnson & Johnson common stock for Kenvue Inc. ("Kenvue") common stock. The final exchange ratio was 8.0324 shares of Kenvue common stock per share of Johnson & Johnson common stock accepted in the exchange offer.
F2 Grant of Deferred Share Units acquired under the Issuer's Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date).